High materiality7/10
Climb Bio price target raised to $25 from $18 at Oppenheimer
Why it may matterVerify against the original reporting
Bullish setup driven by upgrade
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Analyst upgrade; Oppenheimer raises PT to $25 from $18 for CLYM.
- PT raised to $25 from $18; stock at $15.36
Key facts
- 01
Target: $25
- 02
Posted price: $15.36
- 03
Analyst firm: Oppenheimer
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.